Fortive (NYSE:FTV) reported quarterly earnings of $0.63 per share which beat the analyst consensus estimate of $0.60 by 5 percent. This is a 14.86 percent decrease over earnings of $0.74 per share from the same period last year. The company reported quarterly sales of $1.26 billion which beat the analyst consensus estimate of $1.22 billion by 3.20 percent. This is a 26.55 percent decrease over sales of $1.71 billion the same period last year.
Freeline Announces Orphan Drug Designations for FLT201 for the Treatment of Gaucher Disease
Freeline Therapeutics Holdings plc (NASDAQ:FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering
